HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

ausing bone marrow dysfunction and enlargement of the lymph nodes, liver and spleen. Standard front line therapy consists of alkylating agent based drug regimens. Fludarabine is the only approved drug for the treatment of patients who have failed alkylating agents. No approved therapy is available for patients who fail fludarabine therapy.

CAMPATH appears to work in CLL by depleting malignant CLL cells, which bear the CD52 antigen. CAMPATH is a humanized monoclonal antibody which is directed against the CD52 antigen found on normal and malignant lymphocytes, on normal macrophages and monocytes, but has not been detected on hematopoietic stem cells.

CAMPATH therapy is associated with significant lymphopenia. The lymphopenia resolves in some, but not all, patients over weeks to months after cessation of CAMPATH therapy.

"Early studies suggested the promise of CAMPATH. This study appears to confirm the decision to submit a BLA to the FDA," said Kanti R. Rai, M.D., Chief, Division Hematology-Oncology, Long Island Jewish Medical Center. "CAMPATH may very well become the next new and promising monoclonal antibody therapy for patients with cancer. For our patients with CLL, CAMPATH may change the expectation from one of relentlessly progressive deterioration on palliative therapies to the hope of extended survival," said Dr. Rai, who is also one of the trial's principal investigators and an internationally recognized expert in CLL.

ILEX and LeukoSite are developing CAMPATH through a joint venture that was established in May 1997. Clinical trials in the treatment of non-Hodgkin?s lymphoma, CLL, and other malignancies expressing CD52 are being planned.

"CAMPATH is the most advanced of ILEX's nine compounds and we are anxious to make it available to patients," said Richard L. Love, president and chief executive officer of ILEX.

ILEX Oncology, Inc. is a drug development company focused exclusively on accelerated development of drugs fo
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:10/19/2014)... 19, 2014 Visual Impact Frequency ... just been released to the public generating a ... building and fitness community. The commotion surrounding the ... Vin Delmonico prompting an investigative review. , "Many ... what is commonly known as a training 'plateau' ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
(Date:10/19/2014)... OCTOBER 20, 2014 – The U.S. Government has ... treat Alzheimer,s disease by 2025. However, a workgroup ... the research milestones in the U.S. Government,s National ... in scope, increased in scale, and adequately funded ... series of proposals by the workgroup to enlarge ...
(Date:10/19/2014)... NY (PRWEB) October 19, 2014 Nearly ... Bard Inc. and Johnson & Johnson’s Ethicon unit have ... Court, where two state proceedings are continuing to move ... 7,201 lawsuits have been filed over products part of ... Case List updated on October 11th, 2014, which showed ...
(Date:10/19/2014)... Denver, Colorado (PRWEB) October 19, 2014 ... consider joining Colorado and Washington State in the outright ... some words of advice for pro-cannabis activists in those ... framework is in place, or prepare for chaos. , ... The Denver-based shop is one of Colorado’s first recreational ...
Breaking Medicine News(10 mins):Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Litigations in New Jersey Tally More than 8,700 Lawsuits against C.R. Bard and Ethicon, Bernstein Liebhard LLP Reports 4Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 2Health News:Cannabis CEO Warns Those States Considering a Legal Marijuana Market to Do Their Homework First 3
(Date:10/18/2014)... , Oct. 18, 2014  In a ... Campaign (HRC), the nation,s largest lesbian, gay, bisexual ... the use of Truvada for Pre-Exposure Prophylaxis (PrEP). ... used to prevent the spread of a disease ... only brand name anti-HIV drug combination currently approved ...
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
(Date:10/17/2014)... MONICA, Calif. , Oct. 17, 2014 A ... Orange County doctor with a history of ... television ad for Yes on Prop 46 today, highlighting how ... random drug and alcohol testing. The ad ... goes off reading "911-Report To ER."  Proposition 46 will enact ...
Breaking Medicine Technology:HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 2Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 3Victim Of Negligence At Hands Of A Drunk Doctor, A Physician and Consumer Advocates Release New Yes on 46 TV Ad, "On Call" 4
Cached News: